Conservative management of pediatric pancreatic pseudocyst using octreotide acetate.
Pancreatic pseudocysts in children are rare. A total of 213 cases have been reported in the literature, the majority secondary to trauma (65%). Treatment options range from conservative, non-operative management to operative drainage. Octreotide acetate, a long-acting analog of somatostatin, is a synthetic peptide with a variety of endocrine and gastrointestinal functions. Octreotide has been successfully used following pancreatic surgery to reduce exocrine function and most recently in the management of adult pancreatic pseudocysts. We report the efficacy of octreotide, as an adjunct to treatment, in two children with pancreatic pseudocyst. Each child was treated conservatively with bowel rest, hyperalimentation, and octreotide acetate (2.5 micrograms/kg SQ QD). Complete resolution of the pseudocysts occurred within 5 weeks. We conclude that octreotide acetate is a safe and potentially effective adjunct in the treatment of pediatric pancreatic pseudocyst, and should be added to the management of pseudocyst before drainage procedures.
Mulligan
C
C
Department of General Surgery, Eisenhower Army Medical Center, Fort Gordon, GA 30905.
Howell
C
C
Hatley
R
R
Martindale
R
R
Clark
J
J
D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D007223:Infant; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010192:Pancreatic Pseudocyst / Q000209:etiology / Q000628:therapy*
D015282:Octreotide